David G Bear
- Professor, Cellular and Molecular Medicine
- Member of the Graduate Faculty
- (520) 626-1150
- Life Sciences North, Rm. 445
- Tucson, AZ 85724
- dbear@arizona.edu
Biography
David Bear was born and raised in Tucson, Arizona, attended Tucson High School. He received a B.S. degree in Chemistry from the University of Arizona in 1972 and obtained a Ph.D. degree in Chemistry and Biochemistry from the University of California at Santa Cruz in 1978. He was an NIH Postdoctoral Fellow at the University of Oregon Institute of Molecular Biology (1978-1982) and a Visiting Postdoctoral Fellow at the Lineberger Cancer Center at the University of North Carolina Chapel Hill (1982). From 1982 to 2015, Dr. Bear was on the faculty of the University of New Mexico School of Medicine where he was promoted to full professor in 1994. In addition to running a research program funded by NSF, NIH, DOD, MDA and AHA, which focused on messenger RNA synthesis and intracellular trafficking in muscle cells, he served as Chair of the departments of Cell Biology and Physiology (1997-2004) and Chemistry and Chemical Biology (2009-2012). He was Director of Graduate Studies (1988-1994) and Associate Dean for Admissions (1995-2011). In 2016, Dr. Bear joined the faculty of the Department of Cellular and Molecular Medicine at the University of Arizona College of Medicine, where his research interests are focused on the genetics of muscle cell diseases and on new methods for teaching genetics and genomics to medial students and graduate students.
Degrees
- Ph.D. Chemistry
- University of California Santa Cruz, Santa Cruz, California, United States
- Alteration of RNA Secondary Structure by E. coli Ribosomal Protein S1
- B.S. Chemistry
- University of Arizona, Tucson, Arizona, United States
Work Experience
- University of New Mexico School of Medicine (2015 - 2019)
- Karolinska Institute (1999 - 2003)
- Cold Spring Harbor Laboratory (1996)
- University of New Mexico School of Medicine (1982 - 2015)
- University of North Carolina - Chapel Hill, Chapel Hill, North Carolina (1982)
- University of Oregon, Eugene, Oregon (1978 - 1982)
Interests
Research
RNA synthesis and intracellular trafficking in muscle cells and muscle cell diseases
Teaching
Genetics and Molecular Biology for medical students, graduate students, and undergraduate student, as well as medical residents and clinicians
Courses
2024-25 Courses
-
Genetic Medicine
CMM 435 (Spring 2025) -
Genetic Medicine
CMM 535 (Spring 2025) -
Human Genetics Basics
CMM 403 (Spring 2025) -
Human Genetics Basics
CMM 503 (Spring 2025) -
Molecular Medicine
CMM 433 (Spring 2025) -
Molecular Medicine
CMM 533 (Spring 2025) -
Genetic Medicine
CMM 435 (Fall 2024) -
Genetic Medicine
CMM 535 (Fall 2024) -
Human Genetics Basics
CMM 403 (Fall 2024) -
Human Genetics Basics
CMM 503 (Fall 2024) -
Molecular Medicine
CMM 433 (Fall 2024) -
Molecular Medicine
CMM 533 (Fall 2024) -
Thesis
CMM 910 (Fall 2024)
2023-24 Courses
-
Human Genetics Basics
CMM 403 (Summer I 2024) -
Human Genetics Basics
CMM 503 (Summer I 2024) -
Application of Basic Sciences
MED 840 (Spring 2024) -
Genomic Medicine
CMM 534 (Spring 2024) -
Human Genetics Basics
CMM 503 (Spring 2024) -
Genetic Medicine
CMM 535 (Fall 2023) -
Human Genetics Basics
CMM 503 (Fall 2023) -
Molecular Medicine
CMM 533 (Fall 2023) -
Thesis
CMM 910 (Fall 2023)
2022-23 Courses
-
Human Genetics Basics
CMM 503 (Summer I 2023) -
Application of Basic Sciences
MED 840 (Spring 2023) -
Genomic Medicine
CMM 534 (Spring 2023) -
Genetic Medicine
CMM 535 (Fall 2022) -
Molecular Medicine
CMM 533 (Fall 2022) -
Thesis
CMM 910 (Fall 2022)
2021-22 Courses
-
Thesis
CMM 910 (Summer I 2022) -
Application of Basic Sciences
MED 840 (Spring 2022) -
Genomic Medicine
CMM 534 (Spring 2022) -
Thesis
CMM 910 (Spring 2022) -
Genetic Medicine
CMM 535 (Fall 2021) -
Molecular Medicine
CMM 533 (Fall 2021) -
Thesis
CMM 910 (Fall 2021)
2020-21 Courses
-
Application of Basic Sciences
MED 840 (Spring 2021) -
Thesis
CMM 910 (Spring 2021) -
Application of Basic Sciences
MED 840 (Fall 2020) -
Genetic Medicine
CMM 535 (Fall 2020) -
Molecular Medicine
CMM 533 (Fall 2020) -
Thesis
CMM 910 (Fall 2020)
2019-20 Courses
-
Application of Basic Sciences
MED 840 (Spring 2020) -
Genetic Medicine
CMM 535 (Spring 2020) -
Molecular Medicine
CMM 533 (Spring 2020) -
Molecular Medicine
CMM 533 (Fall 2019)
2018-19 Courses
-
Molecular Medicine
CMM 533 (Spring 2019)
Scholarly Contributions
Journals/Publications
- Bear, D. G., Hippel, P. H., & Mcswiggen, J. A. (1988). Interactions of Escherichia coli transcription termination factor rho with RNA. Journal of Molecular Biology. doi:10.1016/0022-2836(88)90305-1More infoIn this paper we examine the binding of Escherichia coli transcription termination factor rho to single-stranded RNA. Random polyribonucleotide copolymers containing low ratios of the fluorescent base 1,N6-ethenoadenosine have been synthesized using polynucleotide phosphorylase. Binding of rho to these polynucleotides elicits a significant increase in fluorescence, thus allowing either the direct monitoring of the titration of these polynucleotides with rho or measurement of the competitive displacement of the protein from these probes with other nucleic acids, even in the presence of biologically significant concentrations of ATP. By these techniques, it is shown that the binding site size (n) of rho protein to polynucleotides is 13(+/- 1) nucleotide residues per rho monomer (or 78(+/- 6) nucleotide residues per rho hexamer). Binding constants (K) and co-operativity parameters (omega) for the binding of rho to these polynucleotides have been measured as a function of nucleotide composition and of salt concentration. The results show that the affinity of rho for cytosine residues is quite strong and salt concentration independent, whilst binding to uridine residues is somewhat weaker and very salt concentration dependent. Poly(rC) and poly(dC) bind to rho competitively and with equal affinity and site size, although poly(rC) is the strongest cofactor for activating rho-dependent ATPase and poly(dC) has no ATPase cofactor activity at all. It is also shown that ATP (or ADP or ATP-gamma-S) binding does not change the binding site size of rho on RNA nor decrease its affinity for RNA binding. Circular dichroism measurements of rho binding to phage R17 RNA suggest that the affinity (K omega) of rho for RNA may be increased by ATP. The possible significance of these results for models of rho-dependent transcription termination is discussed in the companion paper.
- Bear, D. G., Hippel, P. H., Litchman, B. L., & Morgan, W. D. (1985). RNA sequence and secondary structure requiresments for rho-dependent transcription termination. Nucleic Acids Research. doi:10.1093/nar/13.10.3739More infoThe interaction of E. coli termination factor rho with the nascent RNA transcript appears to be a central feature of the rho-dependent transcription termination process. Based on in vitro studies of the rho-dependent termination of the transcript initiated at the PR promoter of bacteriophage lambda, and on earlier studies, Morgan, Bear and von Hippel (J. Biol. Chem. 258, 9565-9574, 1983) proposed a model defining the features of a potential binding site for rho protein on transcripts subject to rho-dependent termination. This model suggested that an effective rho binding site on a nascent RNA transcript should be: (i) greater than 70-80 nucleotide residues in length; (ii) essentially unencumbered with stable secondary structure; (iii) relatively sequence non-specific; and (iv) located within a few hundred nucleotide residues upstream of the potential rho-dependent terminus. In this paper we examine the sequences and secondary structures of several transcripts that exhibit rho-dependent termination to test this hypothesis further. Unstructured regions of approximately the expected size and location were found on all the transcripts examined. Though several short specific sequence elements were found to occur in a very similar arrangement on the lambda PR- and lambda PL-initiated transcripts of lambda phage, no such elements of sequence regularity were found on any of the other rho-dependent transcripts. The results of the sequence comparisons reported here strongly support the generality of the "unstructured binding site" hypothesis for rho-dependent termination.